Introduction
============

The incidence of diabetes mellitus is increasing, and this condition is becoming one of the major causes of morbidity and mortality across the globe ([@b1-ijmm-41-01-0302]). Blood glucose levels are maintained within a narrow range in healthy individuals by the liver through the opposing actions of insulin and glucagon ([@b2-ijmm-41-01-0302]). Hepatic gluconeogenesis, which is inhibited by insulin and stimulated by glucagon, serves an essential role in the maintenance of a normal blood glucose level during fasting. Gluconeogenesis becomes unrestrained in diabetes due to either deficient insulin secretion in type 1 diabetes mellitus or deficient insulin action in type 2 diabetes mellitus, which contributes to hyperglycemia ([@b3-ijmm-41-01-0302]). Therefore, elucidation of the molecular mechanism involved in the regulation of hepatic gluconeogenesis is likely to provide new avenues for the treatment of type 2 diabetes mellitus.

Long non-coding RNAs (lncRNAs) are defined as transcripts of \>200 nucleotides (nt) that do not encode protein. According to their position relative to nearby coding genes, lncRNAs can generally be classified into four categories, namely sense overlap, antisense overlap, bidirectional and intergenic noncoding RNAs ([@b4-ijmm-41-01-0302]). It has been suggested that lncRNAs serve a pivotal role in physiology and disease ([@b5-ijmm-41-01-0302],[@b6-ijmm-41-01-0302]). Morán *et al* ([@b7-ijmm-41-01-0302]) uncovered hundreds of islet lncRNAs by strand-specific analysis, some of which were dysregulated in type 2 diabetes or mapped to genetic loci underlying diabetes susceptibility. In adipose tissue, numerous lncRNAs have been identified to regulate adipogenesis ([@b8-ijmm-41-01-0302]). In muscle cells, H19 LncRNA has been indicated to mediate the regulation of glucose metabolism ([@b9-ijmm-41-01-0302]). However, little is known about the role of lncRNAs in hepatic gluconeogenesis.

In the fasting state, the increased secretion of the catabolic hormone glucagon stimulates gluconeogenesis by triggering the cyclic adenosine monophosphate (cAMP)/protein kinase A pathway and promoting the transcription of gluconeogenic genes ([@b10-ijmm-41-01-0302]). Metformin is currently the first drug of choice for the treatment of type 2 diabetes mellitus ([@b11-ijmm-41-01-0302]). It has been demonstrated that metformin reduces glucose output mainly via the inhibition of gluconeogenesis ([@b12-ijmm-41-01-0302]). However, the exact mechanism remains unclear ([@b13-ijmm-41-01-0302]--[@b15-ijmm-41-01-0302]). To identify whether lncRNAs are involved in the metformin-mediated inhibition of gluconeogenesis, a systematic analysis of the lncRNA expression profile in cAMP-stimulated primary mouse hepatocytes was performed in the present study. The cAMP-induced changes in lncRNA expression that were attenuated by metformin were identified. Among them, the expression levels of eight lncRNAs were validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The aim of the present study was to identify the potential role of lncRNAs in the regulation of gluconeogenesis.

Materials and methods
=====================

Materials
---------

A total of 48 C57Bl/6 mice (age, 8--12 weeks old; weight, 18--20 g) were purchased from Shanghai Slack Experimental Center (Shanghai, China) and were housed in a specific pathogen free (SPF) environment (24--26°C; relative humidity 50--60%) with a 12-h light/dark cycle and free access to food and water. Dulbecco\'s modified Eagle\'s medium (DMEM) and Hank\'s balanced salt solution (HBSS) were obtained from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Hepatocyte medium was purchased from ScienCell Research Laboratories, Inc. (Carlsbad, CA, USA). Sodium pyruvate, sodium lactate, dexamethasone, bovine serum albumin (BSA), 8-bromoadenosine 3′,5′-cyclic monophosphate (8-br-cAMP) and metformin were acquired from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). All the primers used in RT-qPCR were synthesized by Shanghai Sangon Biological Engineering Technology and Services Co., Ltd. (Shanghai, China).

Primary mouse hepatocyte isolation and culture
----------------------------------------------

All experiments were supervised and approved by the laboratory ethics committee of Ruijin Hospital affiliated with Shanghai Jiaotong University School of Medicine (Shanghai, China). Hepatocytes were isolated from 8--12 week old male C57Bl/6 mice. Briefly, following anesthesia, mouse livers were perfused with 10 ml 1X HBSS without calcium, followed by perfusion with 0.05% collagenase IV in calcium-containing HBSS in a recirculating manner. The liver was then detached and filtered through a 70 *μ*m nylon mesh and hepatocytes were sedimented by centrifugation at 200 × g for 5 min at 4°C. The hepatocytes were plated onto 6-well plates and grown in hepatocyte medium supplemented with BSA, penicillin/streptomycin and hepatocyte growth factor. The cultures were maintained at 37°C in humidified atmosphere (95% air and 5% CO~2~). After 24 h, the cells had become attached to the plates and the medium was replaced with low glucose DMEM containing 0.25% BSA with dexamethasone (100 nM) for prestimulation for 12--16 h. The cells were then incubated with 100 *μ*M 8-br-cAMP (a permeable analogue of cAMP) in the presence or absence of 2 mM metformin in glucose-free DMEM containing gluconeogenic substrates (10 mM sodium lactate and 1 mM sodium pyruvate) for 8 h.

RNA extraction and quality control
----------------------------------

Total RNA was extracted from primary mice hepatocytes using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. The RNA purity and concentration was evaluated with a NanoDrop-2000 spectrophotometer (Thermo Fisher Scientific, Inc.). The optical density (OD) absorbance ratio at 260 and 280 nm (A~260~/A~280~ ratio) was \~2.0 and the OD A~260~/A~230~ ratio was \~1.8. RNA integrity was determined by standard denaturing agarose gel electrophoresis, which revealed that the samples were good quality.

Microarray analysis
-------------------

ArrayStar mouse LncRNA microarray version 2.0 (ArrayStar Inc., Rockville, MD, USA) is designed for the global profiling of mouse lncRNAs in hepatocytes isolated from 3 mice (i.e., 3 groups at 3 replicates). The sample preparations and microarray hybridization were performed based on the manufacturer\'s protocols. Briefly, 1 *μ*g total RNA from each sample was amplified and transcribed into fluorescent cRNA using Agilent\'s Quick Amp Labeling kits (Agilent Technologies, Inc., Santa Clara, CA, USA) according to the manufacturer\'s protocol. The labeled cRNAs were hybridized onto the mouse 8×60K LncRNA array. After washing, the arrays were scanned using the Agilent G2505C Microarray Scanner System, and Agilent Feature Extraction software was used to analyze the acquired array images (Agilent Technologies, Inc.). Quantile normalization and subsequent data processing were performed using the GeneSpring GX v12.0 software package (Agilent Technologies, Inc.). The threshold set for significantly differential genes was an absolute log value of fold-change ≥2 and a P-value ≤0.05. The microarray analysis was performed by KangChen Bio-tech Inc. Corporations (Shanghai, China).

RT-qPCR
-------

Following total RNA extraction, as described above, cDNA was synthesized by reverse transcription using Superscript II RT reagent kit (Promega Corporation, Madison, WI, USA) according to the manufacturer\'s protocol. RT-qPCR was performed with the Roche LightCycle^r®^ 480 instrument (Roche Diagnostics, Basel, Switzerland) using SYBR Premix Ex Taq (Takara Bio, Inc., Otsu, Japan) in a final volume of 10 *μ*l. The PCR conditions were as follows: Denaturation at 95°C for 10 sec, 40 cycles at 95°C for 5 sec and 60°C for 31 sec. A melting curve was constructed in the temperature range of 60 to 95°C at the end of the amplification. The sequences of the primers used are shown in [Table I](#tI-ijmm-41-01-0302){ref-type="table"}. Relative gene expression levels were quantified based on the cycle threshold (Cq) values and normalized to the internal control gene β-actin, which received a value of 1. The relative gene expression was calculated using the 2^−ΔΔCq^ method ([@b16-ijmm-41-01-0302]).

Statistical analysis
--------------------

All values are presented as mean ± standard deviation from at least three independent experiments, and P≤0.05 was considered to indicate a statistically significant difference. Differential expression levels of genes were compared using ANOVA for multiple groups or Student\'s t-test for two groups. Statistical analysis was performed by SPSS 18.0 software (IBM, Armonk, NY, USA).

Results
=======

Phosphoenolpyruvate carboxykinase (PEPCK) expression levels under different conditions
--------------------------------------------------------------------------------------

Gluconeogenesis is tightly controlled through the transcriptional regulation of PEPCK, the rate-limiting enzyme of hepatic gluconeogenesis ([@b17-ijmm-41-01-0302]). Metformin has been reported to suppress PEPCK expression in primary hepatocytes ([@b14-ijmm-41-01-0302]). Prior to microarray analysis, the effect of metformin on PEPCK mRNA expression in the primary mouse hepatocytes was investigated. Following the incubation of primary mouse hepatocytes with 100 *μ*M 8-br-cAMP for 8 h, PEPCK mRNA expression was significantly increased, and this increase was significantly suppressed by 2 mM metformin ([Fig. 1](#f1-ijmm-41-01-0302){ref-type="fig"}). This indicates that the experimental conditions are suitable for studying the mechanism of gluconeogenesis. Therefore, the microarray analysis of the lncRNAs expression profile was performed using the same conditions.

Profile of the microarray data
------------------------------

A total of 22,016 lncRNAs were detected in the primary mouse hepatocytes using ArrayStar Mouse LncRNA Microarray version 2.0. The lncRNAs represented in this microarray have been sourced from authoritative databases, including RefSeq, UCSC Knowngenes and Ensembls. Scatter plots were used to assess the variation in the expression of lncRNAs between the cAMP group and the control group ([Fig. 2A](#f2-ijmm-41-01-0302){ref-type="fig"}) or between the metformin group and the cAMP group ([Fig. 2B](#f2-ijmm-41-01-0302){ref-type="fig"}). By setting a threshold for differential expression at fold-change \>2.0-fold, 865 differentially expressed lncRNAs (456 upregulated and 409 downregulated lncRNAs) were identified in the cAMP group vs. the control group. Compared with the cAMP group, 4,580 differentially expressed lncRNAs were identified, of which 2,114 lncRNAs were upregulated and 2,466 lncRNAs were downregulated in the metformin group. Among the cAMP-upregulated lncRNAs, 189 were downregulated by metformin. Among the cAMP-downregulated lncRNAs, 167 were upregulated by metformin. Heatmaps demonstrate the lncRNA expression profiles of the groups, and the expression values of the 30 most strongly cAMP-upregulated and cAMP-downregulated lncRNAs ([Fig. 2C and D](#f2-ijmm-41-01-0302){ref-type="fig"} and [Table II](#tII-ijmm-41-01-0302){ref-type="table"}) reversed by metformin are presented.

Expression signatures of metformin-reversed lncRNAs
---------------------------------------------------

It is likely that these metformin-reversed lncRNAs serve a critical role in the regulation of gluconeogenesis. Therefore, some general signatures of these lncRNAs, such as their sources, classification, length distribution and chromosome distribution, were investigated. A pie chart was constructed to show the number of metformin-reversed lncRNAs collected from different databases ([Fig. 3A](#f3-ijmm-41-01-0302){ref-type="fig"}). There were 78 antisense overlap, 25 bidirectional, 214 intergenic and 39 sense overlap lncRNAs among these lncRNAs ([Fig. 3B](#f3-ijmm-41-01-0302){ref-type="fig"}), which were mainly between 400 and 3,600 nt in length ([Fig. 3C](#f3-ijmm-41-01-0302){ref-type="fig"}). Chromosome distribution analysis demonstrated that these metformin-reversed lncRNAs were located on a number of different chromosomes ([Fig. 3D and E](#f3-ijmm-41-01-0302){ref-type="fig"}).

RT-qPCR validation
------------------

Among the identified metformin-reversed lncRNAs, 8 cAMP-stimulated and metformin-inhibited l ncR NAs (A K1336 02, ENSM UST 0 0 0 0 0138573, ENSMUST00000129953, uc009njr.1, AA591058, NR_027710, NR_030715 and ENSMUST00000145208) were selected for analysis by RT-qPCR in order to verify the microarray data. The expression levels of all 8 cAMP-stimulated lncRNAs were significantly decreased in the presence of metformin as shown by RT-qPCR ([Fig. 4](#f4-ijmm-41-01-0302){ref-type="fig"}), consistent with the results of the microarray analysis.

Associated coding gene expression
---------------------------------

Ponjavic *et al* ([@b18-ijmm-41-01-0302]) emphasized the importance of lncRNA and its adjacent protein-coding gene pairs when investigating the function of lncRNAs. Therefore, using the UCSC genome browser (<http://genome.ucsc.edu/>) and NONCODE database (<http://www.noncode.org>), the sequences of the eight validated lncRNAs and their associated coding genes were obtained (data not shown). The lncRNA ENSMUST00000138573 is a 614-nt antisense overlapping lncRNA associated with the G protein-coupled receptor 155 (Gpr155) gene. LncRNA NR_027710 is a sense overlapping lncRNA, which is located near the PGC-1α gene. Notably, RT-qPCR analysis demonstrated that Gpr155 and PGC-1α displayed a similar expression pattern to their associated lncRNAs under the same treatment conditions ([Fig. 5A and B](#f5-ijmm-41-01-0302){ref-type="fig"}). Therefore, it is possible that the two lncRNAs modulate gluconeogenesis through their associated protein-coding genes.

Discussion
==========

Excessive glucose output via gluconeogenesis is a critical pathological factor contributing to hyperglycemia in type 2 diabetes mellitus, during which the liver synthesizes glucose from non-carbohydrate precursors, including pyruvate and lactate ([@b19-ijmm-41-01-0302],[@b20-ijmm-41-01-0302]). Under the fasting state, increased pancreatic hormone glucagon interacts with the glucagon receptor and activates adenylate cyclase, thus leading to an elevation of intracellular cAMP ([@b10-ijmm-41-01-0302]). Elevated cAMP then triggers gluconeogenesis via activation of the transcriptional factor cAMP-response element binding protein (CREB) ([@b10-ijmm-41-01-0302], [@b21-ijmm-41-01-0302]). It is well known that the activity of the gluconeogenic pathway is controlled by the gene expression of several key enzymes, including PEPCK. A large body of evidence from animal studies and diabetic patients has demonstrated that metformin lowers blood glucose levels by inhibiting gluconeogenesis ([@b12-ijmm-41-01-0302]--[@b14-ijmm-41-01-0302]). The present research team have also observed that metformin decreases glucose production in primary mouse hepatocytes (data not shown). In the present study, cAMP-induced PEPCK mRNA expression was demonstrated to be suppressed by metformin, consistent with previous studies ([@b13-ijmm-41-01-0302],[@b14-ijmm-41-01-0302]).

lncRNAs were initially considered to be transcriptional \'noise\' of the mammalian genome; however, there is considerable evidence that lncRNAs serve key roles in various biological processes via the regulation of gene expression at the level of chromatin remodeling, transcriptional control and post-transcriptional processing ([@b22-ijmm-41-01-0302]). LncRNAs have also been implicated in numerous human diseases, including Alzheimer\'s disease ([@b23-ijmm-41-01-0302]), cardiovascular diseases ([@b24-ijmm-41-01-0302]), diabetes ([@b25-ijmm-41-01-0302]) and various cancers ([@b26-ijmm-41-01-0302]). There are many studies demonstrating that lncRNAs are involved in the differentiation and homeostasis of metabolic tissues, including islets, skeletal muscle and adipose tissues, as summarized in a recent review ([@b27-ijmm-41-01-0302]). Particularly in islets, there is growing evidence that lncRNAs are involved in the determination of β-cell identity and participate in the misregulation of gene expression during type 2 diabetes ([@b7-ijmm-41-01-0302],[@b28-ijmm-41-01-0302]). However, to the best of our knowledge, the effect of lncRNA on hepatic gluconeogenesis has not been elucidated. In the present study, a hepatocyte model with cAMP and metformin treatment was used to better understand the potential role of lncRNAs in the hepatic gluconeogenesis process.

Using microarray analysis, 865 and 4,580 differentially expressed lncRNAs were identified in the cAMP group vs. the control group and the metformin group vs. the cAMP group, respectively. Among the cAMP-regulated lncRNAs, 356 were reversed by metformin treatment, and the expression of 189 AMP-upregulated lncRNAs was decreased by metformin. Previous studies have demonstrated that metformin suppresses the cAMP-stimulated expression of genes involved in gluconeogenesis ([@b14-ijmm-41-01-0302],[@b29-ijmm-41-01-0302]). By analyzing the expression signatures of the metformin-reversed lncRNAs, it was found that the majority were long intergenic noncoding RNAs. Therefore, it is possible that these lncRNAs regulate the expression of neighbouring protein-coding genes. A set of 8 cAMP-upregulated and metformin-downregulated lncRNAs was selected with which to validate the results of the micro-array using RT-qPCR. The results suggest that metformin may decrease gluconeogenesis by globally altering hepatic lncRNA expression.

Although the precise roles of these lncRNAs in gluconeogenesis remain unknown, lncRNAs have been demonstrated to regulate neighbouring gene expression through cis- and trans-mechanisms ([@b5-ijmm-41-01-0302]). Notably, a strong co-expression of lncRNA NR_027710 and PGC-1α was validated by the RT-qPCR analysis in the present study, as shown in [Figs. 4F](#f4-ijmm-41-01-0302){ref-type="fig"} and [5A](#f5-ijmm-41-01-0302){ref-type="fig"}. This implies a potential role of NR_027710 in the regulation of PGC-1α expression. Hormonal signaling regulates hepatic gluconeogenesis by triggering a cascade of transcriptional events involving various transcriptional activators and coactivators, including PGC-1α, CREB and transducer of regulated CREB activity 2 ([@b30-ijmm-41-01-0302]--[@b32-ijmm-41-01-0302]). LncRNA NR_027710 has been found to be transcribed from the natural-sense strand of the gene PGC-1α, which encodes the transcriptional coactivator PGC-1α. Herzig *et al* ([@b30-ijmm-41-01-0302]) demonstrated that PGC-1α is induced by CREB to trigger the expression of gluconeogenic genes. The results of the present study and previous studies ([@b14-ijmm-41-01-0302],[@b17-ijmm-41-01-0302]) demonstrated that 8-br-cAMP caused a significant increase in the PGC-1α transcript, which was suppressed by metformin. According to the bioinformatic analysis, ENSMUST00000138573, a 614-nt lncRNA exhibits a natural antisense association with the coding gene Gpr155 in chromosome 2. In the present study, the expression level of Gpr155 displayed a similar pattern of change to that of lncRNA ENSMUST00000138573. Kobayashi *et al* ([@b33-ijmm-41-01-0302]) revealed that Gpr155 was one of four candidate genes for type 2 diabetes by performing exome sequencing analysis. It has been shown that lncRNAs act as transcriptional cofactors to modulate the transcription of adjacent protein coding genes ([@b34-ijmm-41-01-0302]), which suggests that lncRNA NR_027710 and lncRNA ENSMUST00000138573 may affect the expression of PGC-1α and Gpr155 through an unknown mechanism. These two lncRNA-mRNA gene pairs highlight the importance of lncRNAs in the modulation of glucose homeostasis.

In conclusion, to the best of our knowledge, the present study is the first to reveal the role of lncRNA in gluconeogenesis by conducting a global microarray analysis. It is likely that metformin inhibits hepatic gluconeogenesis by regulating lncRNA expression. In addition, two lncRNAs NR_027710 and ENSMUST00000138573 are associated with PGC-1α and Gpr155, respectively. The two pairs of lncRNAs and coding protein genes exhibit a similar expression pattern, suggesting that lncRNAs may exert their functions through interactions with coding transcripts and proteins in gluconeogenesis. The present study provides a new perspective for understanding the glucose-lowering mechanism of metformin. However, the exact regulatory mechanisms of the specific lncRNAs involved in gluconeogenesis require further investigation, potentially via loss and gain of function studies.
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![Metformin significantly inhibits cAMP-stimulated PEPCK expression. Primary mouse hepatocytes were incubated with 100 *μ*M 8-br-cAMP in the presence or absence of 2 mM metformin for 8 h. PEPCK mRNA expression was detected by reverse transcription-quantitative polymerase chain reaction. Results are representative of three independent experiments. \*\*P\<0.01 vs. control group; ^\#\#^P\<0.01 vs. cAMP group. cAMP, cyclic adenosine monophosphate; PEPCK, phosphoenolpyruvate carboxykinase; 8-br-cAMP, 8-bromoadenosine 3′,5′-cyclic monophosphate.](IJMM-41-01-0302-g00){#f1-ijmm-41-01-0302}

![Comparison of lncRNA expression profiles in primary mouse hepatocytes of the three groups. The differential expression profiles of lncRNAs were analyzed by microarray. Scatter plots are presented to show the lncRNA expression variation between (A) the cAMP group and the control group and (B) the metformin group and the cAMP group. The values on the x- and y-axes in the scatter-plot are the normalized signal values of each group (log~2~ scaled). The lncRNAs above the top green line and below the bottom green line in the scatter plots indicate a \>2-fold-change of lncRNA expression. The heatmaps show (C) the top 30 cAMP-upregulated lncRNAs and (D) the top 30 cAMP-downregulated lncRNAs reversed by metformin. Red indicates a relatively high expression and green indicates a relatively low expression. lncRNA, long non-coding RNA; cAMP, cyclic adenosine monophosphate.](IJMM-41-01-0302-g01){#f2-ijmm-41-01-0302}

![Expression signatures of metformin-reversed lncRNAs regulated by cAMP. (A) The numbers of metformin-reversed lncRNAs from various authorative databases. (B) Classification of reversed lncRNAs demonstrated that these lncRNAs were mainly intergenic. (C) The majority of the metformin-reversed lncRNAs were between 400 and 1,200 nucleotides in length. Analysis of chromosome distribution showed the numbers of (D) cAMP-upregulated and metformin-downregulated lncRNAs and (E) cAMP-downregulated and metformin-upregulated lncRNAs located in different chromosomes. lncRNA, long non-coding RNA; cAMP, cyclic adenosine monophosphate.](IJMM-41-01-0302-g02){#f3-ijmm-41-01-0302}

![Validation results of eight cAMP-upregulated and metformin-downregulated lncRNAs by RT-qPCR are consistent with those of the microarray. Primary mouse hepatocytes were incubated with 100 *μ*M 8-br-cAMP in the presence or absence of 2 mM metformin for 8 h. RT-qPCR demonstrated that cAMP-stimulated (A) AK133602, (B) ENSMUST00000138573, (C) ENSMUST00000129953, (D) uc009njr.1, (E) AA591058, (F) NR_027710, (G) NR_030715 and (H) ENSMUST00000145208 were attenuated by metformin. All results were obtained from three independent experiments. ^\*^P\<0.05 and \*\*P\<0.01 vs. control group; ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. cAMP group. cAMP, cyclic adenosine monophosphate; lncRNA, long non-coding RNA; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.](IJMM-41-01-0302-g03){#f4-ijmm-41-01-0302}

![Expression levels of PGC-1α and Gpr155 are increased by cAMP and are further decreased by metformin treatment. Primary mouse hepatocytes were incubated with 100 *μ*M 8-br-cAMP in the presence or absence of 2 mM metformin for 8 h. (A) PGC-1α and (B) Gpr155 mRNA expression was detected by reverse transcription-quantitative polymerase chain reaction. The experiment was repeated three times with similar results. ^\*^P\<0.05 vs. control group; ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. cAMP group. PGC-1α, peroxisome proliferator-activated receptor-γ coactivator-1 1α, Gpr155, G protein-coupled receptor 155; cAMP, cyclic adenosine monophosphate.](IJMM-41-01-0302-g04){#f5-ijmm-41-01-0302}

###### 

Sequence of the primers used for reverse transcription-quantitative polymerase chain reaction.

  Gene                 Forward sequence (5′ to 3′)   Reverse sequence (5′ to 3′)
  -------------------- ----------------------------- -----------------------------
  PEPCK                GTGCTGGAGTGGATGTTCGG          CTGGCTGATTCTCTGTTTCAGG
  AK133602             GACCAGTCTGACCCCTATCC          TAACCAGCCATTCACCCTC
  ENSMUST00000138573   CCTCAGCACAGAAACCACC           AGCCTGTCCAACTATGCGT
  ENSMUST00000129953   TTCAGCCTACAATCCCAAG           GTGGAATACACCCCGAAGT
  uc009njr.1           TTTGTCGCTCATCCACGCT           GCAAATGGTCCCGCAAATA
  AA591058             GACCACCAGGCAGCACTTC           ACCACACACACCCACACACAC
  NR_027710            TGCCATATCTTCCAGTGACC          TAAGGTTCGCTCAATAGTCTTG
  NR_030715            TGGGGTGGAGAAGACAACA           AGCACAACCACAAGCATCTAC
  ENSMUST00000145208   TCTCAACTCTATGCCGCCTT          GCACACTTCCGCTTCACCT
  Gpr155               GTTTTTCTGTGCCGTGTTTAACT       GGGGGATTCTCTGTCTGCT
  PGC-1α               ATACCGCAAAGAGCACGAGAAG        CTCAAGAGCAGCGAAAGCGTCACAG
  β-actin              GGCTGTATTCCCCTCCATCG          CCAGTTGGTAACAATGCCATGT

PEPCK, phosphoenolpyruvate carboxykinase; Gpr155, G protein-coupled receptor 155; PGC-1α, peroxisome proliferator-activated receptor-γ coactivator-1α.

###### 

Top 30 cAMP-upregulated lncRNAs and cAMP-downregulated lncRNAs reversed by metformin.

  Seqname                  Fold-change   Regulation (cAMP vs. control)   Fold-change   Regulation (metformin vs. cAMP)
  ------------------------ ------------- ------------------------------- ------------- ---------------------------------
  AK008754                 63.58867      Up                              55.04594      Down
  AK036023                 57.2507       Up                              3.325115      Down
  ENSMUST00000138573       37.43524      Up                              2.130461      Down
  uc007biz.1               31.35165      Up                              17.08355      Down
  NR_030715                25.00611      Up                              45.54781      Down
  uc009njr.1               22.53223      Up                              4.457007      Down
  MM9LINCRNAEXON10271^−^   19.73751      Up                              2.071386      Down
  ENSMUST00000129953       18.7799       Up                              8.698158      Down
  uc008hhq.1               15.70811      Up                              8.776502      Down
  AK133602                 15.02128      Up                              8.871666      Down
  ENSMUST00000147868       14.96649      Up                              32.93101      Down
  AA591058                 14.75416      Up                              16.43587      Down
  uc009jlk.1               12.59451      Up                              43.2916       Down
  AK040239                 8.804657      Up                              8.449728      Down
  AK018502                 7.718255      Up                              8.491624      Down
  ENSMUST00000166559       7.339848      Up                              2.552899      Down
  ENSMUST00000164645       6.906824      Up                              2.483507      Down
  uc007otm.1               6.888684      Up                              6.263191      Down
  ENSMUST00000145208       6.529995      Up                              19.36338      Down
  uc007idu.1               6.296531      Up                              3.856799      Down
  AK052609                 6.237578      Up                              7.895747      Down
  CR518961                 6.112049      Up                              2.601747      Down
  ENSMUST00000137582       6.028889      Up                              8.330698      Down
  NR_024513                6.003099      Up                              10.10774      Down
  NR_027901                5.708479      Up                              20.74246      Down
  ENSMUST00000130094       5.705397      Up                              33.7096       Down
  ENSMUST00000142260       5.699138      Up                              15.27239      Down
  ENSMUST00000161491       5.59761       Up                              29.0643       Down
  ENSMUST00000129758       5.463225      Up                              5.843725      Down
  NR_030782                5.312138      Up                              2.623824      Down
  BY008479                 21.01573      Down                            2.650546      Up
  NR_033533                15.91963      Down                            2.650648      Up
  NR_030719                14.39216      Down                            3.259029      Up
  uc.71+                   12.23815      Down                            2.515803      Up
  ENSMUST00000119007       8.960969      Down                            2.669164      Up
  AK018576                 8.671295      Down                            3.36866       Up
  NR_030720                6.8741        Down                            4.131914      Up
  AK171775                 6.527647      Down                            2.402267      Up
  uc008ref.1               6.215065      Down                            5.873268      Up
  ENSMUST00000117185       6.061         Down                            3.369349      Up
  uc008iqy.1               6.043397      Down                            3.388012      Up
  AA636162                 5.986786      Down                            2.320948      Up
  mouselincRNA1303^+^      5.755683      Down                            7.49714       Up
  MM9LINCRNAEXON11420^+^   5.640478      Down                            3.268149      Up
  ENSMUST00000152190       5.534303      Down                            2.962099      Up
  AK148967                 5.531486      Down                            3.036806      Up
  uc007qpd.1               5.508539      Down                            8.222444      Up
  AK140466                 5.259056      Down                            2.131494      Up
  ENSMUST00000169881       5.179452      Down                            3.134108      Up
  uc007cua.1               5.058929      Down                            3.124969      Up
  AI586175                 4.876382      Down                            4.435117      Up
  NR_033629                4.820504      Down                            2.005511      Up
  AK019612                 4.674555      Down                            2.644345      Up
  mouselincRNA1040+        4.510026      Down                            49.62078      Up
  NR_002702                4.507347      Down                            4.266528      Up
  ENSMUST00000129609       4.367185      Down                            5.31341       Up
  ENSMUST00000119828       4.262482      Down                            11.6708       Up
  uc008ijm.1               4.213697      Down                            4.486794      Up
  AK035610                 4.009485      Down                            2.407165      Up
  uc009spu.1               3.959393      Down                            2.946273      Up

The table lists only some of the results for lncRNAs with an up- or downregulation in expression in the cAMP group compared with the control group and in the metformin group compared with the cAMP group. Seqname, lncRNA name; fold-change, absolute fold-change between the compared groups; up, upregulation; down, downregulation; cAMP, cyclic adenosine monophosphate; lncRNA, long non-coding RNA.
